Human Galectin 4
Mostrando 1-4 de 4 artigos, teses e dissertações.
-
1. Clonagem, expressão, purificação e estudos estruturais dos domínios de reconhecimento de carboidratos (CRDs) da galectina-4 humana / Cloning, expression, purification and structural studies of the carbohydrate-recognition domains (CRDs) of human galectin-4
The galectin family comprises a group of lectins where the carbohydrate-recognition domains (CRDs) display specific affinity for ß-galactosides. They are widely distributed in normal and neoplasic cells of different organisms and are involved in a great diversity of cellular mechanisms. The galectins have been focus of recent studies, mainly for their invol
Publicado em: 2009
-
2. Crystallization and preliminary X-ray diffraction analysis of a protease-resistant mutant form of human galectin-8
A protease-resistant mutant form of human galectin-8 has been crystallized and diffraction data have been collected to 3.4 Å resolution.
International Union of Crystallography.
-
3. Galectin-3 Overexpression in Invasive Laryngeal Carcinoma, Assessed by Computer-assisted Analysis
The larynx is the most common site of malignancy in the upper aerodigestive tract. In Brazil, malignant laryngeal lesions represent 2% of all cancers, with ∼3000 annual deaths. The association between human papillomavirus (HPV) and laryngeal cancer is still controversial. The aim of the present retrospective study was to determine the expression of galecti
Histochemical Society.
-
4. Galectin-8 Induces Apoptosis in Jurkat T Cells by Phosphatidic Acid-mediated ERK1/2 Activation Supported by Protein Kinase A Down-regulation*
Galectins have been implicated in T cell homeostasis playing complementary pro-apoptotic roles. Here we show that galectin-8 (Gal-8) is a potent pro-apoptotic agent in Jurkat T cells inducing a complex phospholipase D/phosphatidic acid signaling pathway that has not been reported for any galectin before. Gal-8 increases phosphatidic signaling, which enha
American Society for Biochemistry and Molecular Biology.